Larimar Therapeutics Inc (LRMR) FinancialsLRMRLarimar Therapeutics Inc

Evaluating the bottom line, Larimar Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -139.63%, provide a clear picture of how effectively LRMR converts its operational activities into shareholder value.

In the context of the broader market, LRMR competes directly with industry leaders such as RCKT and SABS. With a market capitalization of $217.12M, it holds a significant position in the sector. When comparing efficiency, LRMR's gross margin of N/A stands against RCKT's N/A and SABS's N/A. Such benchmarking helps identify whether Larimar Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company has shown a consistent negative net income, with Q2 2026 reporting a loss of $32.8 million, and an EPS of -0.30, though this is an improvement from -0.41 in the previous year. Current assets are strong at $160.7 million, providing a cash runway into Q3 2027.